The Luxembourg Parkinson's Study is an ongoing longitudinal nationwide monocentric observational study. It collects extensive clinical, molecular, genetic, and digital device-based longitudinal data, as well as foreseen post-mortem diagnostic validation (Hipp et al., 2018). The cohort consists of more than 1,600 participants from Luxembourg and the Greater Region, comprising patients with typical PD or atypical parkinsonism - irrespective of disease stage, age, cognitive status, comorbidities, or linguistic background - followed-up annually and age- and sex-matched healthy control subjects followed-up every 4 years. To provide a large, longitudinally followed, and deeply phenotyped set of patients and controls for clinical and fundamental research on PD, the investigators have implemented an open-source digital platform that has been partly harmonized with other international PD cohort studies. This effort is flanked by comprehensive biosampling efforts assuring high quality and sustained availability of body liquids and tissue biopsies (including blood, urine, stool, saliva, hair, skin biopsy and cerebrospinal fluid). All data and samples are stored, curated, and integrated into state-of-the-art data and biobank facilities.
Study Type
OBSERVATIONAL
Enrollment
1,800
Observational study with sample and data collection
Centre Hospitalier de Luxembourg (CHL), "Parkinson's Research Clinic"
Luxembourg, Luxembourg
RECRUITINGClinical and Epidemiological Investigation Center (CIEC)
Luxembourg, Luxembourg
RECRUITING1. Establish an open collection of a large set of diverse longitudinal bio-samples and data for research in 800 PD patients and 800 controls
1.1. Samples will be aliquoted and stored according to the highest standards at the IBBL for future research.
Time frame: through study completion, an average of 8 years
2. Stratification of parkinsonism into subtypes and definition of individual progression trajectories of PD.
2.1. Identify PD patients' subgroups with a similar pattern of disease progression. datasets.
Time frame: through study completion, an average of 8 years
Determine Parkinson's disease biomarker signatures
3.1. Identify new and early diagnostic biomarkers
Time frame: through study completion, an average of 8 years
Develop a mechanistic understanding of the disease
4.1. Understand the mechanisms of PD pathogenesis.
Time frame: through study completion, an average of 8 years
Inform future studies testing new therapies for Parkinson's disease
1.1. Enable future studies, such as clinical trials, by sharing the findings of mechanisms of PD pathogenesis and identifying new therapeutic targets.
Time frame: through study completion, an average of 8 years
Harmonization of data with international Parkinson's disease cohort studies
2.1. Data collected in this study will be harmonized with the international PD research community through an open-source digital platform.
Time frame: through study completion, an average of 8 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.